Inflazome IP Portfolio Strengthened with
 Patents Granted in US and Europe

January 13, 2020

Dublin (IE), Cambridge (UK), Brisbane (AU) | 13 January 2020: Inflazome, the pioneering inflammasome biotech company developing multiple small molecule drugs that block harmful inflammation, today announces that the United States Patent and Trademark Office (USPTO) and the European Patent Office (EPO) will grant the patent application WO 2016/131098 as US 10,538,487 on 21 January 2020 and EP 3,259,253 on 15 January 2020.


The patents provide for compounds which have advantageous properties and show useful activity in the inhibition of NLRP3 inflammasome activation. Such compounds are useful in the treatment of a wide range of disorders, including Parkinson’s, Alzheimer’s and Motor Neurone Disease, in which inflammation arising from the NLRP3 inflammasome is implicated as a key factor. Inflazome currently has two ongoing Phase I studies with Inzomelid and Somalix.


These new patents strengthen Inflazome’s intellectual property portfolio that extends to 43 patent families, reinforcing the company’s leading innovative position in discovering targeted therapies for inflammatory-driven diseases.


Matt Cooper, Chief Executive Officer of Inflazome, commented: “The granting of these pioneering patents marks another milestone for Inflazome and strengthens our IP portfolio. The patents granted in the US and Europe cover our lead clinical candidate, Inzomelid. Both Inzomelid and our second drug, Somalix, are in the final stages of Phase I safety and tolerability trials for inflammatory diseases. We look forward to driving these drugs into further trials to help people with debilitating diseases.” 


The patent was originally filed by the University of Queensland and Trinity College Dublin following a highly productive collaboration between Inflazome founders, Professor Matt Cooper (University of Queensland) and Professor Luke O’Neill (Trinity College Dublin). It was licensed exclusively to Inflazome when the company was founded.





Contacts


Inflazome:

Dr Jeremy Skillington | VP Business Development 

E: j.skillington@inflazome.com


Media:


FTI Consulting


UK & International | Ciara Martin/Tim Stamper

T: +44 20 37271000


Ireland & International | Jonathan Neilan/Patrick Berkery 

T: +353 1 7650800 


E: StratCommEMEAInflazome@fticonsulting.com

Media

If you are a member of the media and have a media query please contact:

Contact Us

Speak to us about
a better tomorrow

Contact Us

×